Gedatolisib Patent Expiration
Gedatolisib was first introduced by Celcuity Inc
Gedatolisib Patents
Given below is the list of patents protecting Gedatolisib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Revtorpyk | US12350276 | Methods For The Treatment Of Cancer Using 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea | Aug 31, 2042 | Celcuity |
| Revtorpyk | US12109308 | Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yljcarbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea | Jan 02, 2041 | Celcuity |
| Revtorpyk | US8039469 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors | Dec 17, 2029 | Celcuity |
| Revtorpyk | US8217036 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors | May 22, 2029 | Celcuity |
| Revtorpyk | US8575159 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors | May 22, 2029 | Celcuity |
| Revtorpyk | US8748421 | Triazine Compounds As P13 Kinase And Mtor Inhibitors | May 22, 2029 | Celcuity |
| Revtorpyk | US9174963 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors | May 22, 2029 | Celcuity |
Gedatolisib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List